LBI 1026
Alternative Names: LBI-1026Latest Information Update: 28 Aug 2025
At a glance
- Originator Luminus Biosciences
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Epilepsy; Glaucoma; Nausea and vomiting; Neuropathic pain; Pain
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for preclinical development in Epilepsy in USA
- 28 Aug 2025 No recent reports of development identified for preclinical development in Glaucoma in USA
- 28 Aug 2025 No recent reports of development identified for preclinical development in Nausea and vomiting in USA